Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Abstract Background New oral anticoagulants (NOACs) have been becoming prevalent in
recent years and are increasingly used in the treatment of port vein thrombosis. The …

Background The nonvitamin K antagonist oral anticoagulants (NOACs) have become the
mainstay anticoagulation therapy for patients requiring oral anticoagulants (OACs) in the …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Background Phase III trials should be integrated by post authorisation safety studies (PASS)
to confirm their conclusions in real life. In this setting, comorbidities are commonly more …

Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …

Background Previous studies have shown that patients with a history of atrial fibrillation (AF)
have a higher risk of developing coronary slow flow (CSF). However, whether AF episode …

Patients who are at risk for venous thromboembolism may require prophylaxis with oral
anticoagulant agents. In South Africa, available oral anticoagulant agents include warfarin …

ANTIKOAGULAATIOHOIDON VUOTOHAITTOJEN RISKITEKIJÄT JA RISKIPROFIILIN
TUNNISTAMINEN Page 1 ANTIKOAGULAATIOHOIDON VUOTOHAITTOJEN RISKITEKIJÄT JA …

Patients who are at risk for venous thromboembolism may require prophylaxis with oral
anticoagulant agents. In South Africa, available oral anticoagulant agents include warfarin …